Mitsui Ventures 三井ベンチャーズ(MVC、MCVP) ベンチャーキャピタル ベンチャー 三井物産 起業

NEWS 2005

[10/04/2005]

MicroMed Retains CCG for Investor and Media Relations Program

HOUSTON--(BUSINESS WIRE)--Oct. 4, 2005--MicroMed Cardiovascular, Inc. (OTCBB:MMCV), a leader in miniaturized implantable ventricular assist technology, announced today that it has retained CCG to plan and conduct a program of investor relations and media relations activities.

"Having become a public company very recently, we feel that the time has come to enlist the skills and efforts of corporate communications specialists who understand our industry space and appreciate our technology leadership," said Travis E. Baugh, a co-founder and President and CEO of MicroMed Cardiovascular. "We selected CCG based on its strong track record in conducting targeted, structured communications campaigns for other small-cap and microcap life science companies."

Mr. Baugh continued, "CCG's team structure gives us the personal access we would expect from a boutique PR firm, along with the medical technology knowledge and contacts in the investment and media communities of a much larger agency. We look forward to working with CCG in raising awareness of our company and the DeBakey VADR, our next-generation life-saving mechanical assist solution in pivotal clinical trials to treat congestive heart failure, which is America's most deadly disease."

About our Technology

MicroMed's initial platform in heart failure products is the DeBakey Ventricular Assist Device (VAD) for the treatment of advanced heart failure. There are currently 15 million victims of heart failure worldwide. With less than 1% of donor organs available for heart transplantation, MicroMed believes that the DeBakey VAD is a key alternative for this population. The DeBakey VAD represents a new generation of miniaturized implantable mechanical circulatory support devices. Designed in collaboration with NASA, the Baylor College of Medicine and Drs. Michael DeBakey and George Noon, the DeBakey VAD is intended for adult and pediatric advanced heart failure patients who can no longer provide necessary blood flow with their native heart. The proprietary technology is intended to take over virtually all left ventricular function and concurrently monitor real-time flow parameters.

About CCG Investor Relations

CCG is one of the country's leading investor relations and strategic communications firms. Its clients include numerous companies in the life science and technology sectors. The full-service investor relations agency has corporate headquarters in Los Angeles, with additional offices in New York City and Newport Beach, Calif. For further information, contact CCG directly or visit the Company's website at www.ccgir.com

About MicroMed Cardiovascular, Inc.

MicroMed currently has two ongoing clinical investigations in over thirty leading U.S. heart transplant centers to evaluate the safety and effectiveness of the DeBakey VAD for use as a Bridge to Heart Transplantation and for Destination Therapy for patients ineligible for heart transplant. The DeBakey VAD system has been awarded the CE mark for Bridge to Transplant and Destination Therapy for commercial distribution in Europe. The DeBakey VAD Child, the only implantable VAD approved for use in children, is already commercially released in the U.S. and CE mark approved for distribution in Europe. Over 340 adult and pediatric devices have been implanted. MicroMed's manufacturing facility is located in Houston, and is ISO 9001 certified.

http://www.micromedtech.com/

Contacts

MicroMed Cardiovascular, Inc.
Media Contact:
Tammy Pitts, 713-580-8289
tpitts@micromedcv.com
or
CCG Investor Relations:
Sean Collins, 310-477-9800
or
CCG Media Contact:
Saskia Sidenfaden, 310-477-9800